VRTX Q2 2022 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.2B+22.5% YoY

Gross Profit

$1.9B88.1% margin

Operating Income

$1.1B50.4% margin

Net Income

$811M36.9% margin

EPS (Diluted)

$3.13

QoQ Revenue Growth

+4.7%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$1.1B

Stock-Based Comp.

$114M

Balance Sheet

Total Assets

$15.6B

Total Liabilities

$3.6B

Stockholders' Equity

$11.9B

Cash & Equivalents

$8.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.2B	$1.8B	+22.5%
Gross Profit	$1.9B	$1.6B	+23.6%
Operating Income	$1.1B	-$38M	+3019.0%
Net Income	$811M	$67M	+1111.1%

Revenue Segments

TRIKAFTA/KAFTRIO

$1.9B86%

KALYDECO

$139M6%

ORKAMBI

$122M6%

SYMDEKO/SYMKEVI

$43M2%

Geographic Segments

UNITED STATES

$1.4B64%

Europe

$656M30%

Other, Non U.S.

$126M6%